In BRAF V600E mutated melanoma, where activation of the MAPK pathway is due to the mutated BRAF protein only, treatment with a MEKi does not lead to reactivation of MEK through CRAF (Lito et al. 2014). The gene discussed is BRAF; the disease is melanoma.